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Abstract
Purpose: The purpose of this study was to determine whether pulmonary oligometastases from colorectal cancer have greater
radioresistance than that of pulmonary oligometastases from other cancers and whether good local control can be achieved by
dose escalation in stereotactic body radiotherapy. Materials and Methods: This systematic review and meta-analysis were
conducted according to the preferred reporting items for systematic reviews and meta-analyses statement and methods. Studies
were obtained from a database search of PubMed, Web of Science, and Google Scholar for publications using search terms
designed to identify studies on “oligometastases,” “lung,” “stereotactic radiotherapy,” and “colorectal cancer.” For meta-analysis
1, studies that showed the number of local failures after stereotactic body radiotherapy for pulmonary metastases from colorectal
carcinoma and other cancers were included. For meta-analysis2, studies in which a comparison was made of local control rates of
pulmonary metastases from colorectal carcinoma by stereotactic body radiotherapy with a higher dose and that with a lower dose
were included. A meta-analysis was performed using Mantel-Haenszel statics with the fixed or random-effect model by Review
Manager 5.3. Results: Eighteen retrospective studies with 1920 patients with pulmonary oligometastases were used in meta-
analysis 1. The local control rate in patients with pulmonary oligometastases from colorectal cancer was significantly lower than
that in patients with pulmonary oligometastases from other cancers (odds ratio¼ 3.10, P < .00001). Next, 8 retrospective studies
with 478 patients were included in meta-analysis 2 for dose escalation. Better local control was achieved by a higher prescription
dose than by a lower prescription dose (odds ratio ¼ 0.16, P < .00001). Conclusion: Our meta-analysis indicated that local
control of pulmonary oligometastases from colorectal cancer by stereotactic body radiotherapy was significantly worse than that
of pulmonary metastases from other cancers; however, our results also indicated that good local control of pulmonary oligo-
metastases from colorectal cancer can be achieved by dose escalation.
Keywords
oligometastases, colorectal cancer, stereotactic radiotherapy, lung metastases, meta-analysis
Abbreviations
CI, confidence interval; OR, odds ratio; PRISMA, preferred reporting items for systematic reviews and meta-analyses; PTV,
planning target volume; SBRT, Stereotactic body radiotherapy.
Received: January 13, 2018; Revised: April 28, 2018; Accepted: July 25, 2018.
Pulmonary oligometastases from colorectal cancer should be
resected as much as possible.1 Stereotactic body radiotherapy
(SBRT) for pulmonary oligometastases has been used com-
monly as an alternative method to metastomy in patients
who cannot receive surgery; however, some studies have
shown that pulmonary oligometastases from colorectal cancer
are more difficult to control by SBRT than are pulmonary
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oligometastases from other cancers.2-4 On the other hand, some
researchers have reported that there was no significant differ-
ence in local control.5 All of the studies were relatively small
studies, and to the best of our knowledge, there has been no
prospective study in which this issue was evaluated.
Whether SBRT can be a practical alternative treatment to
metastomy has remained controversial. We therefore evalu-
ated local control by SBRT for pulmonary oligometastases
from colorectal cancer compared to local control by SBRT
for pulmonary oligometastases from other cancers using
pooled analysis. There have been some studies showing that
dose escalation could achieve better local control in patients
who received SBRT for pulmonary oligometastases from
colorectal cancer.4,6 Unfortunately, there has also been no
prospective study on this issue. Since pulmonary oligome-
tastases from colorectal cancer might have greater radiore-
sistance, we also evaluated the efficacy of dose escalation in
SBRT for pulmonary oligometastases from colorectal cancer
using meta-analyses.
Purpose
The purpose of this study was to determine whether pulmonary
oligometastases from colorectal cancer have greater radioresis-
tance than that of pulmonary oligometastases from other can-
cers and whether good local control can be achieved by dose
escalation in SBRT.
Materials and Methods
This systematic review and meta-analysis were conducted
according to the preferred reporting items for systematic
reviews and meta-analyses (PRISMA) statement and meth-
ods. Studies were obtained from a database search of PubMed,
Web of Science, and Google Scholar for publications up until
December 2017 using search terms designed to identify stud-
ies on “oligometastases,” “lung,” “stereotactic radiotherapy,”
and “colorectal cancer.” The exclusion criteria were as fol-
lows: (1) case report, editorial, and specialist experience; (2)
only abstract; and (3) articles written in languages other than
English (Figure 1). Two investigators (K.J. and H.M.)
selected trials independently for 2 meta-analyses to determine
whether pulmonary oligometastases from colorectal cancer
have greater radioresistance than pulmonary oligometastases
from other cancers (meta-analysis 1) and whether good local
control can be achieved by dose escalation in SBRT (meta-
analysis 2). For meta-analysis 1, studies that showed the num-
ber of local failures after SBRT for lung metastases from
colorectal carcinoma and other cancers were included. For
meta-analysis 2, studies in which a comparison was made of
local control rates for lung metastases from colorectal carci-
noma by SBRT with a higher dose and that with a lower dose
were included.
The corresponding authors of the candidate studies were
contacted via e-mail in the case of missing data or the require-
ment for additional information regarding their studies.
Figure 1. Flow diagram of the search process.
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A meta-analysis was performed using Mantel-Haenszel statics
with the fixed or random-effect model by Review Manager 5.3
(Cochrane Collaboration, London, United Kingdom). Dichot-
omous data were calculated by the odds ratio (OR) with 95%
confidence intervals (CIs).
The Q test was used to calculate the inconsistency index I2
value. Due to the low sensitivity of the Cochrane Q test, the
significance level a ¼ 0.1 was used for conservation, with P >
.1 indicating no statistical heterogeneity between studies and
P < .1 indicating heterogeneity. Inconsistency index I2 was
used to quantitatively evaluate heterogeneity. When I2 was
<25%, the fixed effect model was used for meta-analysis.
When I2 was more than 25% and less than 50%, the random
effect model was used. When I2was more than 50%, the source
of the heterogeneity was analyzed first, and if there was no
obvious clinical heterogeneity and the source of heterogeneity
could not be found, the random effect model was used. A P < .05
was considered significant for all analyses.
Results
Figure 1 shows the results of the search strategy and all of the
studies that were included and excluded. Data from 18 retro-
spective studies with 1920 patients were used in the meta-
analysis. The patients included 619 patients with pulmonary
oligometastases from colorectal cancer treated by SBRT and
1301 patients with pulmonary oligometastases from other
cancers treated by SBRT (meta-analysis 1;2-5,7-20 Table 1).
The local control rate in patients with pulmonary oligometas-
tases from colorectal cancer was significantly lower than that
in patients with pulmonary oligometastases from other can-
cers (OR ¼ 3.17, 95% CI: 1.98-5.08, P < .00001) with









BED10 Local Control Rate
Aoki7 CRC* 15 3 31.7 months 50 Gy/5 fractions 100 GyBED 3 years: 47.6%
non-CRC 61 1 3 years: 97.5%
Baschnagel8 CRC 17 4 27.6 months 60 Gy/4 fractions 132 GyBED 2 years: 80%
non-CRC 30 0 2 years: 100%
Binkley9 CRC 26 9 22 months 25 Gy/1 faraction or 50 Gy/4 fractions 85 GyBED 2 years: 57.6%
non-CRC 96 9 2 years: 90.1%
Franceschini10 CRC 99 19 24.2 months 48 Gy/4 fractions 105.6 GyBED 3 years: 75.7%
non-CRC 101 8 3 years: 88.2%
Hamamoto12 CRC 8 6 19 months 48 Gy/4 fractions 105.6 GyBED 25%
non-CRC 4 1 75%
Helou4 CRC 101 24 22 months 52 Gy/4 fractions 119.6 GyBED 2 years: 76.4%
non-CRC 83 5 2 years: 91.7%
Inoue13 CRC 37 7 NA 48 Gy/4 fractions 105.6 GyBED 81%
non-CRC 50 4 92%
Navarria14 CRC 29 3 18 months 48 Gy/4 fractions 105.6 GyBED 89.7%
non-CRC 15 4 73.3%
Norihisa21 CRC 9 3 27 months 48 Gy/4 fractions 105.6 GyBED 66.7%
non-CRC 25 1 96%
Oh15 CRC 7 1 21 months 60 Gy/5 fractions 132 GyBED 85.7%
non-CRC 60 2 96.7%
Okunieff16 CRC 14 3 14.9 months 50 Gy/ 10 fractions 75 GyBED 78.6%
non-CRC 35 5 85.7%
Osti5 CRC 23 1 15 months 30 Gy/1 fraction 120 GyBED 95.7%
non-CRC 53 9 83.0%
Rieber11 CRC 153 20 14.3 months NA 84.4 GyBED 86.9%
non-CRC 545 53 90.3%
Singh17 CRC 13 5 16.7 months 50 Gy/5 fractions 100 GyBED 61.50%
non-CRC 21 0 100%
Sulaiman18 CRC 11 5 17 months NA 110 GyBED 54.50%
non-CRC 36 5 86.10%
Takahashi19 CRC 7 2 20 months 48 Gy/4 fractions 105.6 GyBED 2 years: 67%
non-CRC 35 4 2 years: 89%
Takeda3 CRC 21 8 29 months 50 Gy/5 fractions 100 GyBED 2 years: 73%
non-CRC 23 0 15 months 2 years: 94%
Yamamoto2 CRC 29 12 35 months 48 Gy/4 fractions 105.6 GyBED 2 years: 25.5%
non-CRC 28 6 2 years: 70.0%
Abbreviations: BED, biological effective dose; CRC, colorectal cancer; NA, not available.
Jingu et al 3
substantial heterogeneity (P ¼ .02, I2 ¼ 47%; Figure 2). Fun-
nel plots showed that there was no significant publication bias
(Figure 3).
Among the studies on SBRT for pulmonary metastases from
colorectal cancer, 8 retrospective studies with 478 patients
were included in the meta-analysis for dose escalation:
222 patients who were treated with a higher dose and 256
patients who were treated with a lower dose (meta-analysis
[2])4,6,9,20-24 (Table 2). Better local control was achieved by a
higher prescription dose than by a lower prescription dose (OR
¼ 0.16, 95% CI: 0.09-0.28, P < .00001) with no statistical
heterogeneity (P¼ .36, I2¼ 9%; Figure 4). Funnel plots showed
that there was no significant publication bias (Figure 5).
Discussion
First, our results showed that it was more difficult to control
pulmonary oligometastases from colorectal cancer by SBRT
than pulmonary oligometastases from other cancers.
Some investigators have reported that metastases from col-
orectal cancer have radioresistance. Laarhoven et al showed
that metastases of colorectal cancer contain large amounts of
hypoxic cells compared to those in metastases of other cancers
and are therefore radioresistant25; however, this must be only
one of the reasons for local control by SBRT for metastases
from colorectal cancer being poor. In our previous study, we
showed that pulmonary oligometastases from colon cancer was
more difficult to control by SBRT than those from rectal can-
cer.6 This may be due to molecular differences (eg, KRAS and
BRAF status and microsatellite instability); however, the exact
reasons are also unknown.
Next, the present meta-analysis indicated that dose
escalation was important for local control of pulmonary
oligometastases from colorectal cancer as well as hepatic oli-
gometastases26; however, the appropriate total dose and appro-
priate dose per fraction in SBRT for pulmonary
oligometastases from colorectal cancer have still not been
determined. In past studies, there were notable differences in
prescription methods (eg, for the isocenter and for the periph-
ery of the planning target volume [PTV]) as well as in total
dose and dose per fraction. In some studies, 2- to 3-year local
Figure 2. Forest plot showing the association between local control rate and subgroup (colorectal cancer vs others).
Figure 3. Funnel plots for publication bias for local control in patients
with pulmonary metastases from colorectal cancer compared with that
in patients with pulmonary metastases from other cancers.
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control rates by 100 to 105.6 GyBED10, calculated using the
linear-quadratic (LQ) model with a/b ¼ 10 Gy, with prescrip-
tion for the isocenter were 24% to 75.7%,2,4,7,10,19,24,27 while in
other studies, 2- to 3-year local control rates by 95.8 to 150
GyBED10 with prescription for the periphery of the PTV were
52.7% to 100%,3,8-10,15,21,22,24,27-31,32 although there were
many variations in prescription methods for the periphery of
the PTV. Klement reported that the a–b ratio of pulmonary
metastases from noncolorectal cancer was 21.6 and that the
a–b ratio of pulmonary metastases from colorectal cancer was
43.1.33 If the a–b ratio of pulmonary metastases from color-
ectal cancer is very high as Klement reported, both the total
dose and dose per fraction are important. He recommended
more than 3  17 Gy to be given over a course of 5 days to
the isocenter in order to control 90% of metastases from color-
ectal cancer after 1 year. It is difficult to determine the appro-
priate prescription dose because there are many differences
among studies; however, the present meta-analysis suggested
that better local control would be achieved by a higher dose.
We recommend a prescription dose of >100 Gy of BED10 to the
periphery of the PTV in SBRT for pulmonary oligometastases
from colorectal cancer. In some past studies, oligometastases
including those in the liver, lung, and lymph nodes were ana-
lyzed collectively. However, Ahmed et al showed that control
of liver metastases was more difficult than that of lung






















Jingu6 28 months 132 GyBED 24 1 3 years: 95.5% 105.6 GyBED 51 28 3 years: 59.6%
Norihisa20 27 months 132 GyBED 6 0 3 years: 100% 105.6 GyBED 3 2 NA
Bae21 28 months 180 GyBED 29 5 3 years: 69% 124.8 GyBED 12 9 3 years: 49%
Helou4 22 months 150 GyBED 45 3 2 years: 90% 119.6 GyBED 56 21 2 years: 70%
Kinj22 33 months 180 GyBED 75 14 2 years: 82.1% 87.5 GyBED 12 5 2 years: 57.1%
Comito23 24 months 180 GyBED 6 0 3 years: 100% 105.6 GyBED 54 13 3 years: 70%
Jung24 42.8 months 150 GyBED 23 3 3 years: 84% 105.6 GyBED 56 16 3 years: 64.6%
Binkley9 22 months 112.5 GyBED 14 4 2 years: 62.5% 87.5 GyBED 12 6 2 years: 16.7%
Abbreviations: BED, biological effective dose; NA, not available.
Figure 4. Forest plot showing the association between local control rate and subgroup (higher dose vs lower dose) in patients with pulmonary
oligometastases from colorectal cancer.
Figure 5. Funnel plots for publication bias for local control with
higher dose in patients with pulmonary metastases from colorectal
cancer compared to that of lower dose in patients with pulmonary
metastases from other cancers.
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metastases.34 Furthermore, Ahmed et al and Fode et al revealed
that pulmonary metastases could be controlled more easily than
metastases in other sites.28,35 Thus, investigation that includes
oligometastases in several organs is not appropriate. In the
present study, we therefore used data only for patients with
pulmonary oligometastases.
A retrospective study by the Japanese Radiation Oncology
Study Group showed, by multivariate analysis, that adjuvant
chemotherapy after SBRT was a favorable prognostic factor for
local control in patients with pulmonary oligometastases from
colorectal cancer.6 Thibault et al also showed by multivariate
analysis that previous chemotherapy improved local control of
lung metastases treated by SBRT.36 Systemic therapy with
SBRT might improve not only overall survival but also local
control; however, the safety and efficacy of systemic therapy
with SBRT have still not been established. Prospective studies
on SBRT concurrent with systemic therapy including molecu-
lar targeted drug therapy for oligometastases are needed.
There was a major limitation in the present study. Most of
the data used for analyses were from retrospective studies
except for a few phase II studies, which were relatively
small-scale studies, because there were no randomized trials
to evaluate our queries. However, to the best of our knowledge,
this is the first pooled analysis in patients treated by SBRT for
pulmonary oligometastases from colorectal cancer. Prospective
large randomized trials are needed.
Conclusion
Our meta-analysis indicated that local control of pulmonary
oligometastases from colorectal cancer by SBRT was signifi-
cantly worse than that of pulmonary metastases from other
cancers; however, the results of the present study also indicated
that good local control of pulmonary oligometastases from
colorectal cancer can be achieved by dose escalation.
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